Skip to main content
Top
Published in: Respiratory Research 1/2009

Open Access 01-12-2009 | Research

Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum

Authors: David J Serisier, Mary P Carroll, Janis K Shute, Simon A Young

Published in: Respiratory Research | Issue 1/2009

Login to get access

Abstract

Background

Prior microrheologic assessments of selected, microlitre plugs of cystic fibrosis (CF) sputum suggest no intrinsic rheologic abnormality. However, such analyses may not be representative of CF sputum as a whole. We therefore reassessed this question using whole sputum macrorheology. Additionally, we wished to further explore the relationships between sputum rheology, inflammation and infection.

Methods

Dynamic oscillatory macrorheometry was performed on whole expectorated sputum from stable adults with CF (n = 18) and COPD (n = 12) and induced sputum from normal controls (n = 7). Concomitant sputum inflammatory mediator levels were measured in CF and COPD samples. Sputum collected from CF subjects (n = 6) at commencement and completion of intravenous antibiotic therapy for an infective exacerbation was also assessed.

Results

CF sputum neutrophil elastase activity (NE) was significantly related to degree of sputum purulence (p = 0.049) and correlated significantly with measures of sputum viscoelasticity (r = 0.696, p = 0.008 for storage modulus G' at 9 Hz). There were significant differences in viscoelasticity between subject groups when samples were compared irrespective of appearance/degree of sputum purulence. However, the macrorheology of mucoid CF sputum did not differ from normal sputum (eg median (range) G' at 9 Hz 2.25 (0.79, 3.26) vs 2.04 (1.4,4.6) Pa, p = 1). In contrast, mucoid COPD samples demonstrated significantly greater viscoelasticity (G' at 9 Hz 4.5 (2.4, 23) Pa) than sputum from both CF (p = 0.048) & normal subjects (p = 0.009). Antibiotic therapy during exacerbations was associated with significant reductions in CF sputum viscoelasticity, with mean (SD) G' at 9 Hz decreasing from 28.5 (11.5) Pa at commencement to 6.4 (4.6) Pa on day 7 (p = 0.01).

Conclusion

The macrorheologic properties of whole, mucoid CF sputum are not different from normal, confirming the results of prior microrheologic studies. Instead, CF sputum viscoelasticity is related to secondary infection, decreases with intravenous antibiotic therapy and correlates with inflammation. In contrast, COPD sputum demonstrates inherently greater viscoelasticity, providing a novel target for potential therapeutic interventions.
Literature
1.
go back to reference Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005–1015.CrossRefPubMed Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005–1015.CrossRefPubMed
2.
go back to reference Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC: The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001, 8:149–58.CrossRefPubMed Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC: The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001, 8:149–58.CrossRefPubMed
3.
go back to reference Puchelle E, De Bentzmann S, Zahm J: Physical and functional properties of airway secretions in cystic fibrosis – therapeutic approaches. Respiration 1995,62(suppl 1):2–12.PubMed Puchelle E, De Bentzmann S, Zahm J: Physical and functional properties of airway secretions in cystic fibrosis – therapeutic approaches. Respiration 1995,62(suppl 1):2–12.PubMed
4.
go back to reference Powell K, Zeitlin PL: Therapeutic approaches to repair defects in dF508 CFTR folding and cellular targeting. Adv Drug Deliv Re 2002, 54:1395–1408.CrossRef Powell K, Zeitlin PL: Therapeutic approaches to repair defects in dF508 CFTR folding and cellular targeting. Adv Drug Deliv Re 2002, 54:1395–1408.CrossRef
5.
go back to reference Ramsey BW: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335:179–187.CrossRefPubMed Ramsey BW: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335:179–187.CrossRefPubMed
7.
go back to reference Charman J, Reid L: Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology 1972, 9:185–199.PubMed Charman J, Reid L: Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology 1972, 9:185–199.PubMed
9.
go back to reference Lethem MI, James SL, Marriott C: The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis 1990, 142:1053–1058.CrossRefPubMed Lethem MI, James SL, Marriott C: The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis 1990, 142:1053–1058.CrossRefPubMed
10.
go back to reference Balfour-Lynn IM, Klein NJ, Dinwiddie R: Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997, 77:124–30.CrossRefPubMedPubMedCentral Balfour-Lynn IM, Klein NJ, Dinwiddie R: Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997, 77:124–30.CrossRefPubMedPubMedCentral
11.
go back to reference Broughton-head V, Carroll M, Shute JK: Unfractionated heparin reduces the elasticity and yield stress of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1240–1249.CrossRefPubMed Broughton-head V, Carroll M, Shute JK: Unfractionated heparin reduces the elasticity and yield stress of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1240–1249.CrossRefPubMed
12.
go back to reference Jeanneret-Grosjean A, Michoud MC, King M, Liote H, Amyot R: Sampling technique and rheology of human tracheobronchial mucus. Am Rev Respir Dis 1988, 137:707–710.CrossRefPubMed Jeanneret-Grosjean A, Michoud MC, King M, Liote H, Amyot R: Sampling technique and rheology of human tracheobronchial mucus. Am Rev Respir Dis 1988, 137:707–710.CrossRefPubMed
13.
go back to reference Sanders NN, de Smedt SC, van Rompaey E, Simoens P, de Baets F, Demeester J: Cystic Fibrosis sputum. A barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000, 162:1905–1911.CrossRefPubMed Sanders NN, de Smedt SC, van Rompaey E, Simoens P, de Baets F, Demeester J: Cystic Fibrosis sputum. A barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000, 162:1905–1911.CrossRefPubMed
14.
go back to reference Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, Sterk PJ: Sputum induction. Eur Respir J 2002,20(Suppl 37):3–8. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, Sterk PJ: Sputum induction. Eur Respir J 2002,20(Suppl 37):3–8.
15.
go back to reference Baldrey PE, Josse SE: The measurement of sputum viscosity. Am Rev Respir Dis 1968, 98:392–398. Baldrey PE, Josse SE: The measurement of sputum viscosity. Am Rev Respir Dis 1968, 98:392–398.
16.
go back to reference Broughton-Head VJ, Smith JR, Shur J, Shute JK: Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther 2007, 20:708–717.CrossRefPubMed Broughton-Head VJ, Smith JR, Shur J, Shute JK: Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther 2007, 20:708–717.CrossRefPubMed
17.
go back to reference Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK: Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:352–355.CrossRefPubMed Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK: Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:352–355.CrossRefPubMed
18.
go back to reference Stockley R, Bayley D, Hill S, Hill A, Crooks S, Campbell E: Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001, 56:366–372.CrossRefPubMedPubMedCentral Stockley R, Bayley D, Hill S, Hill A, Crooks S, Campbell E: Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001, 56:366–372.CrossRefPubMedPubMedCentral
19.
go back to reference Deneuville E, Perrot-Minot C, Pennaforte F, Roussey M, Zahm JM, Clavel C, Puchelle E, de Bentzmann S: Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med 1997, 156:166–72.CrossRefPubMed Deneuville E, Perrot-Minot C, Pennaforte F, Roussey M, Zahm JM, Clavel C, Puchelle E, de Bentzmann S: Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med 1997, 156:166–72.CrossRefPubMed
20.
go back to reference Kim JS, Okamoto K, Rubin K: Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis. Chest 2006, 129:1148–1154.CrossRefPubMed Kim JS, Okamoto K, Rubin K: Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis. Chest 2006, 129:1148–1154.CrossRefPubMed
21.
go back to reference McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, Alton DW: Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. Eur Respir J 2004, 24:95–100.CrossRefPubMed McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, Alton DW: Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. Eur Respir J 2004, 24:95–100.CrossRefPubMed
22.
go back to reference Bush A, Payne D, Pike S, Jenkins G, Henke MO, Rubin BK: Mucus properties in children with primary ciliary dyskinesia. Chest 2006, 129:118–123.CrossRefPubMed Bush A, Payne D, Pike S, Jenkins G, Henke MO, Rubin BK: Mucus properties in children with primary ciliary dyskinesia. Chest 2006, 129:118–123.CrossRefPubMed
23.
go back to reference Perez A, Issler AC, Cotton CU, Kelley TJ, Verkmann AS, Davis PB: CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007, 292:L383-L395.CrossRefPubMed Perez A, Issler AC, Cotton CU, Kelley TJ, Verkmann AS, Davis PB: CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007, 292:L383-L395.CrossRefPubMed
24.
go back to reference Goldmann MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic that is inactivated in cystic fibrosis. Cell 1997, 88:553–560.CrossRef Goldmann MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic that is inactivated in cystic fibrosis. Cell 1997, 88:553–560.CrossRef
25.
go back to reference Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM: Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface liquid. Am J Respir Cell Mol Biol 2001, 25:21–25.CrossRefPubMed Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM: Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface liquid. Am J Respir Cell Mol Biol 2001, 25:21–25.CrossRefPubMed
26.
go back to reference Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCRay PB Jr, Nauseef WM, Dupuy C, Banfi B: A novel host defense system of the airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:174–183.CrossRefPubMed Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCRay PB Jr, Nauseef WM, Dupuy C, Banfi B: A novel host defense system of the airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:174–183.CrossRefPubMed
27.
go back to reference Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, Ciaccia A, Cavallesco G, Chung KF, Papi A: Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004, 45:477–484.CrossRefPubMed Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, Ciaccia A, Cavallesco G, Chung KF, Papi A: Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004, 45:477–484.CrossRefPubMed
28.
29.
go back to reference Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK: MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004, 31:86–91.CrossRefPubMed Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK: MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004, 31:86–91.CrossRefPubMed
30.
go back to reference Inoue D, Kubo H, Sasaki T, Yasuda H, Numasaki M, Sasaki H, Yamaya M: Erythromycin attenuates MUC5AC synthesis and secretion in cultured human tracheal cells infected with RV14. Respirology 2008, 13:215–220.CrossRefPubMed Inoue D, Kubo H, Sasaki T, Yasuda H, Numasaki M, Sasaki H, Yamaya M: Erythromycin attenuates MUC5AC synthesis and secretion in cultured human tracheal cells infected with RV14. Respirology 2008, 13:215–220.CrossRefPubMed
31.
go back to reference Ou XM, Feng YL, Wen FO, Wang K, Yang J, Deng ZP, Liu DS, Li YP: Macrolides attenuate mucus hypersecretion in rat airways through inactivation of NF-kappaB. Respirology 2008, 13:63–72.CrossRefPubMed Ou XM, Feng YL, Wen FO, Wang K, Yang J, Deng ZP, Liu DS, Li YP: Macrolides attenuate mucus hypersecretion in rat airways through inactivation of NF-kappaB. Respirology 2008, 13:63–72.CrossRefPubMed
32.
go back to reference King M, Dasgupta B, Tomkiewicz RP, Brown NE: Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997, 156:173–177.CrossRefPubMed King M, Dasgupta B, Tomkiewicz RP, Brown NE: Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997, 156:173–177.CrossRefPubMed
33.
go back to reference Albertini-Yagi CS, Oliveira RC, Vieira JE, Negri EM, de Oliveira LR, Saldiva PH, Lorenzi-Filho G: Sputum induction as a research tool for the study of human respiratory mucus. Respir Physiol Neurobiol 2005, 145:101–110.CrossRefPubMed Albertini-Yagi CS, Oliveira RC, Vieira JE, Negri EM, de Oliveira LR, Saldiva PH, Lorenzi-Filho G: Sputum induction as a research tool for the study of human respiratory mucus. Respir Physiol Neurobiol 2005, 145:101–110.CrossRefPubMed
34.
go back to reference Baconnais S, Tirouvanziam R, Zahm JM, de Bentzmann S, Peault B, Balossier G, Puchelle E: Ion composition and rheology of airway liquid from cystic fibrosis fetal tracheal xenografts. Am J Respir Cell Mol Biol 1999, 20:605–611.CrossRefPubMed Baconnais S, Tirouvanziam R, Zahm JM, de Bentzmann S, Peault B, Balossier G, Puchelle E: Ion composition and rheology of airway liquid from cystic fibrosis fetal tracheal xenografts. Am J Respir Cell Mol Biol 1999, 20:605–611.CrossRefPubMed
Metadata
Title
Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum
Authors
David J Serisier
Mary P Carroll
Janis K Shute
Simon A Young
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2009
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-10-63

Other articles of this Issue 1/2009

Respiratory Research 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.